OTLKW - Outlook Therapeutics® to Present at Guggenheim's 5th Annual Inflammation Neurology & Immunology (INI) Conference | Benzinga
ISELIN, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced that Russell Trenary, President and CEO of Outlook Therapeutics will participate in a fireside chat at Guggenheim's 5th Annual Inflammation, Neurology & Immunology (INI) Conference, being held in New York, NY on Tuesday, November 7, 2023 at 1:50 PM ET.
In addition to the fireside chat, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
A live audio webcast of the fireside chat will be accessible ...